| Authors: |
Sasi BK; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School; Boston, Massachusetts., Tarantelli C; Institute of Oncology Research, Faculty of Biomedical Sciences, USI; Bellinzona., Martindale S; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School; Boston, Massachusetts., Civanelli E; Institute of Oncology Research, Faculty of Biomedical Sciences, USI; Bellinzona., Cannas E; Institute of Oncology Research, Faculty of Biomedical Sciences, USI; Bellinzona., Sartori G; Institute of Oncology Research, Faculty of Biomedical Sciences, USI; Bellinzona., Arribas AJ; Institute of Oncology Research, Faculty of Biomedical Sciences, USI; Bellinzona., Fernandes SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School; Boston, Massachusetts., Shupe SJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School; Boston, Massachusetts., Machado JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School; Boston, Massachusetts., Tyekucheva S; Department of Data Sciences, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, Massachusetts., Ren Y; Department of Data Sciences, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, Massachusetts., Lahn M; iOnctura SA; Geneva., Van der Veen L; iOnctura BV; Amsterdam, Netherlands., Di Conza G; iOnctura SA; Geneva., Bertoni F; Institute of Oncology Research, Faculty of Biomedical Sciences, USI; Bellinzona, Switzerland; Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale; Bellinzona. francesco.bertoni@ior.usi.ch., Brown JR; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School; Boston, Massachusetts, USA; Chronic Lymphocytic Leukemia Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School; Boston, MA. jennifer_brown@dfci.harvard.edu. |
